BioSpace News Archive

Mesa Laboratories, Inc. announced results for the fourth quarter and full year ended March 31, 2022.

Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle Libre 3 system for use by people four years and older6 living with diabetes.

I-Mab (the “Company”) (Nasdaq: IMAB), today announced the completion of patient enrollment in a Phase 3 clinical trial (TALLER) of highly differentiated long-acting recombinant human growth hormone eftansomatropin alfa (also known as TJ101), which is being investigated as a weekly treatment for pediatric growth hormone deficiency (PGHD) in China.

Edgewise Therapeutics, Inc. announced that members of its senior management team will participate in the following upcoming investor conferences.

NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced the publication of long-term efficacy and safety data based on analyses at 109 weeks from the 192-week open-label extension trial of a Phase 2 study of VILTEPSO® (viltolarsen) injection in the Journal of Neuromuscular Diseases.

At a time when hospitals are under unprecedented logistical and financial strain, a new industry-wide report illuminates the potential for saving money and reducing waste and emissions by extending the life of “single-use” medical devices through reprocessing.

Takeda Pharmaceutical Company Limited announced that it will present data at two upcoming scientific congresses this spring: the 58th Annual Meeting of the American Society of Clinical Oncology, June 3-7 in Chicago, Ill. and the 30th Congress of the European Hematology Association, June 9-12 in Vienna, Austria.

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, is pleased to announce the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration for its Phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”).

Goldfinch Bio to Present Initial Data from Phase 1 Clinical Trial of GFB-024 at American Diabetes Association 82 nd Scientific Sessions and Endocrine Society’s Annual Meeting, ENDO 2022.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Melinda Brown has been appointed as a Director on the Company’s Board of Directors and Chair of the Board’s Audit Committee.